Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P900033/S115

INTEGRA Dermal Regeneration Template, Integra Meshed Dermal Regeneration Template, and Integra Omnigraft Dermal Regen

Integra Lifesciences Corp. · Decision date Sep 9, 2025

FDA DECISIONP900033/S115

What did the FDA decide?

FDA records P900033/S115 as a supplement to PMA P900033, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 9, 2025.

FDA approval order statement

reclassifying cleanroom for Integra Dermal Regeneration Template (IDRT) product family
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Sep 9, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P900033/S115
Regulatory pathway
PMA supplement
Product code
MGR
Decision code
OK30
Decision date
Sep 9, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Dressing, wound and burn, interactive.

Product code
MGR
FDA device class
3

For the original device and its historical approval scope, see PMA P900033. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P900033 · Original PMA

    INTEGRA DERMAL REGENERATION TEMPLATE

  2. P900033/S115 received

    Application receipt date recorded by FDA.

  3. P900033/S115 · FDA decision

    30-Day Notice

  4. P900033/S116 · Related supplement

    INTEGRA Dermal Regeneration Template; Integra Meshed Dermal Regeneration Template; Integra Omnigraft Dermal Regenera

  5. P900033/S117 · Related supplement

    INTEGRA Dermal Regeneration Template, Integra Meshed Dermal Regeneration Template, and Integra Omnigraft Dermal Rege

Timeline entries are records held by MedtechLedger for P900033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P900033

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Integra Lifesciences Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
105 Morgan Ln., Plainsboro, NJ, 08536

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records